Ascletis Pharmaceuticals-B (01672) announced on the morning of September 22nd that its weight-loss without muscle-loss drug candidate, ASC47, combined with semaglutide, achieved positive results in a clinical trial in obese subjects. On day 29, the 30mg ASC47 plus semaglutide group demonstrated a 56.2% improvement in weight loss compared to semaglutide alone.

The study, conducted in the United States, enrolled 28 obese subjects. Results showed that the combination of ASC47 and semaglutide significantly improved gastrointestinal tolerability compared to semaglutide alone, with a 6.7% incidence of vomiting in the combination group compared to 57.1% in the semaglutide alone group. Furthermore, the ultra-long-acting subcutaneous depot formulation of ASC47 resulted in less weight regain after discontinuation, supporting the potential use of once-monthly ASC47 as a maintenance therapy for weight loss.

The study also showed that the 30mg and 60mg ASC47 groups significantly reduced low-density lipoprotein cholesterol compared to the semaglutide monotherapy group. ASC47 has a half-life of up to 30 days and showed a sustained weight loss advantage even after discontinuation of treatment for 4 weeks.

Dr. Jinzi Wu, Founder, Chairman, and CEO of Ascletis, stated that this study provides important proof-of-concept data that will serve as a key basis for the design of a subsequent Phase IIb combination study, which may include a monthly subcutaneous administration of ASC47 in combination with ASC35.

The Company cautions that there can be no assurance that ASC47, ASC30 and/or ASC35 will ultimately be successfully developed, marketed and/or commercialized.

https://finance.eastmoney.com/a/202509223519679327.html